Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3SLC6A2
The experimentally established mechanism targets of Racephedrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.71 |
| ▸ | ADRA1A known ✓ | P35348 | 2/20 | 0.71 |
| ▸ | SLC6A2 known ✓ | P23975 | 2/20 | 0.46 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.71 |
| ▸ | RGS12 | O14924 | 1/20 | 0.71 |
| ▸ | GLA | P06280 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.71 |
| ▸ | TSHR | P16473 | 1/20 | 0.71 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
| ▸ | HTR2A | P28223 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | THPO | P40225 | 1/20 | 0.71 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Racephedrine SCHEMBL8017708 | 1.00 | ADRA2C (0.71) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Pseudoephedrine SCHEMBL2081239 | 1.00 | ADRA2C (0.71) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Pseudoephedrine SCHEMBL3079358 | 0.98 | ADRA2C (0.69) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Racephedrine SCHEMBL3079361 | 0.98 | ADRA2C (0.69) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Racephedrine SCHEMBL1785211 | 0.98 | ADRA2C (0.69) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Pseudoephedrine SCHEMBL2323883 | 0.92 | ADRA2C (0.73) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Pseudoephedrine SCHEMBL8728628 | 0.90 | ADRA2C (0.71) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Racephedrine SCHEMBL8728630 | 0.90 | ADRA2C (0.71) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Racephedrine SCHEMBL8733657 | 0.85 | ALDH1A1 (0.67) | ADRA2CADRA1ACHRM2RGS12GLA | |
| Pseudoephedrine SCHEMBL8733656 | 0.85 | ALDH1A1 (0.67) | ADRA2CADRA1ACHRM2RGS12GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0751927-A4 | SYNTHESIS OF COMPOUNDS WITH PREDETERMINED CHIRALITY | CALIFORNIA INST OF TECHN (US) | 1998-07-29 | — | — | EP | claimed |
| EP-0751927-A1 | SYNTHESIS OF COMPOUNDS WITH PREDETERMINED CHIRALITY | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1997-01-08 | — | — | EP | claimed |
| WO-1995025714-A1 | SYNTHESIS OF COMPOUNDS WITH PREDETERMINED CHIRALITY | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1995-09-28 | — | — | WO | claimed |
| EP-2988597-B1 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | HARVARD COLLEGE (US) | 2022-06-08 | — | — | EP | disclosed |
| US-10913764-B2 | Macrolides and methods of their preparation and use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-02-09 | — | — | US | disclosed |
| CN-111825733-A | Macrolides and methods of making and using the same | 哈佛大学的校长及成员们 | 2020-10-27 | — | — | CN | disclosed |
| US-20180298048-A1 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-10-18 | — | — | US | disclosed |
| US-9982005-B2 | Macrolides and methods of their preparation and use | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-05-29 | — | — | US | disclosed |
| EP-2988597-A2 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | President and Fellows of Harvard College (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20160052951-A1 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2016-02-25 | — | — | US | disclosed |
| WO-2014165792-A2 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-10-09 | — | — | WO | disclosed |
| EP-1030868-A2 | DESIGN OF COILED-COIL DIMER DERIVED ANTAGONISTS OF 4-HELIX BUNDLE CYTOKINE SPECIFIC RECEPTORS | EUROPÄISCHES LABORATORIUM FÜR MOLEKULARBIOLOGIE (EMBL) (DE) | 2000-08-30 | — | — | EP | disclosed |
| EP-1001970-A1 | DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES | PFIZER INC. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-2000006561-A1 | TRICYCLIC SULFONAMIDES AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| WO-1999025732-A2 | DESIGN OF COILED-COIL DIMER DERIVED ANTAGONISTS OF 4-HELIX BUNDLE CYTOKINE SPECIFIC RECEPTORS | Europäisches Laboratorium für Molekularbiologie (EMBL) (DE) | 1999-05-27 | — | — | WO | disclosed |
| WO-1998058947-A1 | DIPEPTIDE DERIVATIVES AS GROWTH HORMONE SECRETAGOGUES | PFIZER INC. (US) | 1998-12-30 | — | — | WO | disclosed |
| EP-0751927-A4 | SYNTHESIS OF COMPOUNDS WITH PREDETERMINED CHIRALITY | CALIFORNIA INST OF TECHN (US) | 1998-07-29 | — | — | EP | disclosed |
| US-5760237-A | Synthesis of l-azatyrosine using pseudoephedrine as a chiral auxiliary | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-06-02 | — | — | US | disclosed |
| EP-0751927-A1 | SYNTHESIS OF COMPOUNDS WITH PREDETERMINED CHIRALITY | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1997-01-08 | — | — | EP | disclosed |
| WO-1995025714-A1 | SYNTHESIS OF COMPOUNDS WITH PREDETERMINED CHIRALITY | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1995-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160052951-A1 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | CYP11B2, ERG28, DHCR7 | ADRA2C 1367/4885ADRA1A 1455/4885SLC6A2 4727/4885 |
| US-10913764-B2 | Macrolides and methods of their preparation and use | CYP11B2, ERG28, DHCR7 | ADRA2C 1367/4885ADRA1A 1455/4885SLC6A2 4727/4885 |
| US-20180298048-A1 | MACROLIDES AND METHODS OF THEIR PREPARATION AND USE | CYP11B2, ERG28, DHCR7 | ADRA2C 1367/4885ADRA1A 1455/4885SLC6A2 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.